Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
Estrogen-receptor-positive HER-2-negative advanced breast cancer patients had significantly improved progression-free survival when treated with an oral combination regimen consisting of gairdrestrant, a novel, next-generation selective estrogen receptor degrader, and full antagonist, compared to a standard combination approach. These findings from the Phase 3 AVERA breast cancer study are presented today by Dr. Erica Meyer of…
